Furthermore, it will also inform on the potential effects of pharmaceutical targeting of Akt signaling during disease states in which embryonic-like programs, including tissue formation, repair, and cancer progression, can be reactivated (Fazilaty and Basler, 2023). The gene discussed is AKT1; the disease is cancer.